Phytochemicals targeting Alzheimer's disease via the AMP-activated protein kinase pathway, effects, and mechanisms of action
- PMID: 38442672
- DOI: 10.1016/j.biopha.2024.116373
Phytochemicals targeting Alzheimer's disease via the AMP-activated protein kinase pathway, effects, and mechanisms of action
Abstract
Alzheimer's disease (AD), characterized by cognitive dysfunction and other behavioral abnormalities, is a progressive neurodegenerative disease that occurs due to aging. Currently, effective drugs to mitigate or treat AD remain unavailable. AD is associated with several abnormalities in neuronal energy metabolism, such as decreased glucose uptake, mitochondrial dysfunction, and defects in cholesterol metabolism. Amp-activated protein kinase (AMPK) is an important serine/threonine protein kinase that regulates the energy status of cells. AMPK is widely present in eukaryotic cells and can sense and regulate energy metabolism to maintain energy supply and demand balance, making it a promising target for energy metabolism-based AD therapy. Therefore, this review aimed to discuss the molecular mechanism of AMPK in the pathogenesis of AD to provide a theoretical basis for the development of new anti-AD drugs. To review the mechanisms of phytochemicals in the treatment of AD via AMPK pathway regulation, we searched PubMed, Google Scholar, Web of Science, and Embase databases using specific keywords related to AD and phytochemicals in September 2023. Phytochemicals can activate AMPK or regulate the AMPK pathway to exert therapeutic effects in AD. The anti-AD mechanisms of these phytochemicals include inhibiting Aβ aggregation, preventing Tau hyperphosphorylation, inhibiting inflammatory response and glial activation, promoting autophagy, and suppressing anti-oxidative stress. Additionally, several AMPK-related pathways are involved in the anti-AD mechanism, including the AMPK/CaMKKβ/mTOR, AMPK/SIRT1/PGC-1α, AMPK/NF-κB/NLRP3, AMPK/mTOR, and PERK/eIF2α pathways. Notably, urolithin A, artemisinin, justicidin A, berberine, stigmasterol, arctigenin, and rutaecarpine are promising AMPK agonists with anti-AD effects. Several phytochemicals are effective AMPK agonists and may have potential applications in AD treatment. Overall, phytochemical-based drugs may overcome the barriers to the effective treatment of neurodegenerative diseases.
Keywords: AMPK; Alzheimer's disease; Phytochemicals; aging; medicinal plants.
Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Magnolol improves Alzheimer's disease-like pathologies and cognitive decline by promoting autophagy through activation of the AMPK/mTOR/ULK1 pathway.Biomed Pharmacother. 2023 May;161:114473. doi: 10.1016/j.biopha.2023.114473. Epub 2023 Mar 6. Biomed Pharmacother. 2023. PMID: 36889111
-
Oxidative Stress and Decreased Mitochondrial Superoxide Dismutase 2 and Peroxiredoxins 1 and 4 Based Mechanism of Concurrent Activation of AMPK and mTOR in Alzheimer's Disease.Curr Alzheimer Res. 2018;15(8):764-776. doi: 10.2174/1567205015666180223093020. Curr Alzheimer Res. 2018. PMID: 29473507
-
Roles of AMP-activated protein kinase in Alzheimer's disease.Neuromolecular Med. 2012 Mar;14(1):1-14. doi: 10.1007/s12017-012-8173-2. Epub 2012 Feb 26. Neuromolecular Med. 2012. PMID: 22367557 Review.
-
AMPK: A bridge between diabetes mellitus and Alzheimer's disease.Behav Brain Res. 2021 Feb 26;400:113043. doi: 10.1016/j.bbr.2020.113043. Epub 2020 Dec 8. Behav Brain Res. 2021. PMID: 33307136 Review.
-
Signaling pathway cross talk in Alzheimer's disease.Cell Commun Signal. 2014 Mar 28;12:23. doi: 10.1186/1478-811X-12-23. Cell Commun Signal. 2014. PMID: 24679124 Free PMC article. Review.
Cited by
-
Dietary Phytochemicals in Health and Disease: Mechanisms, Clinical Evidence, and Applications-A Comprehensive Review.Food Sci Nutr. 2025 Mar 19;13(3):e70101. doi: 10.1002/fsn3.70101. eCollection 2025 Mar. Food Sci Nutr. 2025. PMID: 40115248 Free PMC article. Review.
-
Novel Compounds as NLRP3 Inhibitors for Treating Alzheimer's Disease and Parkinson's Disease.ACS Med Chem Lett. 2024 Jul 29;15(8):1203-1204. doi: 10.1021/acsmedchemlett.4c00343. eCollection 2024 Aug 8. ACS Med Chem Lett. 2024. PMID: 39140054 Free PMC article.
-
Novel Triazines as NLRP3 Inhibitors for Treating Multiple Diseases.ACS Med Chem Lett. 2024 Nov 18;15(12):2099-2100. doi: 10.1021/acsmedchemlett.4c00552. eCollection 2024 Dec 12. ACS Med Chem Lett. 2024. PMID: 39691525
-
Sex-dependent molecular landscape of Alzheimer's disease revealed by large-scale single-cell transcriptomics.Alzheimers Dement. 2025 Feb;21(2):e14476. doi: 10.1002/alz.14476. Epub 2024 Dec 31. Alzheimers Dement. 2025. PMID: 39737748 Free PMC article.
-
Resveratrol-Enhanced Human Neural Stem Cell-Derived Exosomes Mitigate MPP+-Induced Neurotoxicity Through Activation of AMPK and Nrf2 Pathways and Inhibition of the NLRP3 Inflammasome in SH-SY5Y Cells.Life (Basel). 2025 Feb 13;15(2):294. doi: 10.3390/life15020294. Life (Basel). 2025. PMID: 40003703 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous